Brief: Biomea Fusion Presents Positive Clinical Data From Initial Cohorts Of Ongoing Phase Ii Study (Covalent-111) Of Bmf-219
24/06/2023 03:05
June 23 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION PRESENTS POSITIVE CLINICAL DATA FROM THE
INITIAL
COHORTS OF THE ONGOING PHASE II STUDY (COVALENT-111) OF BMF-219
IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT THE AMERICAN
DIABETES ASSOCIATION (ADA) 83RD SCIENTIFIC SESSIONS; 100 MG
COHORT 3 DEMONSTRATED A 90% RESPONSE RATE AND 70% MAINTAINED OR
IMPROVED TIME IN (NORMAL GLUCOSE) RANGE, WHILE OFF-TREATMENT
Source text for Eikon: ID:nGNX9kWjW5
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes